This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Bioassociate Announces Initiation Of Coverage On KaloBios Pharmaceuticals, Inc.

Stocks in this article: KBIO

TEL AVIV, Israel, February 27, 2013 /PRNewswire/ --

Bioassociate has initiated coverage on KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO).  The Initiation Report contains a detailed discussion of KaloBios' business operations, market dynamics, macroeconomic data and indicators, financial results, potential cash flows, and risks.  The Initiation Report is available at: http://www.bioassociate.com/research-and-publications/publications/.

Dr. Ofir Levi, Bioassociate's CEO: "KaloBios is developing monoclonal antibody (mAb) therapeutics based on the company's proprietary  Humaneeredâ„¢ antibody technology platform, with focus on respiratory related indications. KaloBios' lead program, KB001-A has been licensed by Sanofi Pasteur in 2010 for the  treatment of Pseudomonas aeruginosa-related hospital-acquired infections.  The total  deal value of this licensing agreement is $290 million plus royalties, including a $35 million upfront payment.  KaloBios recently completed an initial public offering and is now trading on the Nasdaq Global Market.  

  We see great potential in KaloBios' technology platform and clinical development programs. Further clinical development advancements are likely to attract additional potential collaborators, which will increase investors' attention.  For these reasons we, at Bioassociate, decided to initiate analysis coverage with a target price of $10.1 per share, which reflects an upside of 47% over the current share price.

About Bioassociate

Bioassociate is an independent investment research firm specialized in the life-science sector.  Bioassociate helps inform readers about small-mid cap life science companies without extensive analyst coverage.  Bioassociate structures its teams with multidisciplinary members to conduct specific assignments.  The Bioassociate team has industry experience as well as consulting and research track record, providing investors with in-depth scientific insights and their financial manifestation.

Disclosure: 

The research report described in this press release is not constructed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer would be illegal.  Bioassociate is not soliciting any action based upon this material.  It does not take into account the particular investment objectives, financial situation, risk profile or other needs of individual investors.  Before acting on any advice or recommendation in this material, an investor should consider whether it is suitable for his/her particular circumstances and, if necessary, seek professional advice.  The report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should be relied upon as such.  Opinions expressed are Bioassociate's current opinions as of the date appearing on this material only; such opinions are subject to change without notice.  

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs